Approximately 15-20% of breast cancers have a triple negative phenotype (negative for ER and PR expression and lack ErbB2 overexpression) that correlates with aggressive cancer and limited treatment options. We have developed an in vivo screen for defining the role of specific kinases in tumorigenesis and metastasis of breast cancer cells. Triple negative and triple positive breast cancer lines were used for shRNA-mediated knock down of specific kinases. The genetically altered lines (expressing luciferase in addition to specific shRNA gene knockdown) are injected into the mammary fat pad of female SCID mice. Tumor growrth and vascularization is monitored longitudinally over an 8 week period using a micro-probe ultrasound system. Metastasis is monitored by bioluminescence imaging. The assay provides an in vivo screen for analysis of proteins that control the growth, vascularization and metastasis of breast tumors. MAPSKs are the first tier of kinases regulating the MAP kinase signaling pathways that lead to the activation of the MAPKs ERK1/2, p38, JNK and ERK5. MAPSKs control expression of genes important for regulating the cell cycle, cytokine and protease expression and apoptosis. In a screen of 9 MAPSKs, MEKK2 was identified as a key regulator of metastasis using MDA-MB-2S1 (triple negative basal) and BT474 (triple positive luminal) breast adenocarcinoma cells in the in vivo tumorigenesis assay. MEKK2 is a MAPSK that regulates the activation of the JNK and ERK5 pathways via activation of MKK7 and MEK5. We have shown that MEKK2 expression is required for EGFR (ErbBI) and ErbB2/Neu activation of ERK5 in MDA-MB-2S1 and BT474 cells, respectively. Our hypothesis is that the MAPSK MEKK2 functions as a critical signaling node within the cell signaling network stimulating tumor growth and metastasis in response to ErbB and possibly other tyrosine kinases. The goal of this proposal is to genetically define the role of MEKK2 in triple negative breast cancer tumor grovirth and metastasis and to develop a MEKK2 small molecule inhibitor.
Specific aim 1 involves defining the role of MEKK2-MEK5-ERK5 signaling in tumorigenesis and metastasis of triple negative breast cancer cells using the in vivo xenograft assay.
In specific aim 2, we propose to elucidate the mechanism by which MEKK2 gets activated by ErbBI/2 using MEKK2 mutants in biochemical and cell-based activation assays.
In specific aim S, a small molecule biochemical screen will be developed to identify compounds that specifically inhibit MEKK2 kinase activity. MEKK2 inhibitors will be tested for MAPK pathway specificity in cell-based assays and profiled for specificity against the kinome. In future studies, these MEKK2 inhibitors will be tested for anti-tumor efficacy in genetically engineered mouse models (GEMMs) of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA156733-01
Application #
8068507
Study Section
Special Emphasis Panel (ZCA1-SRLB-3 (O1))
Project Start
2010-09-01
Project End
2013-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
1
Fiscal Year
2010
Total Cost
$67,053
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kilfoyle, Kimberly A; Des Marais, Andrea C; Ngo, Mai Anh et al. (2018) Preference for Human Papillomavirus Self-Collection and Papanicolaou: Survey of Underscreened Women in North Carolina. J Low Genit Tract Dis 22:302-310
Xiong, Zhaohui; Ren, Shuang; Chen, Hao et al. (2018) PAX9 regulates squamous cell differentiation and carcinogenesis in the oro-oesophageal epithelium. J Pathol 244:164-175
Butler, EboneƩ N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Smith, Jennifer S; Des Marais, Andrea C; Deal, Allison M et al. (2018) Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm Dis 45:42-48
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Anderson, Chelsea; Breithaupt, Lindsay; Des Marais, Andrea et al. (2018) Acceptability and ease of use of mailed HPV self-collection among infrequently screened women in North Carolina. Sex Transm Infect 94:131-137
Jiang, Ming; Li, Haiyan; Zhang, Yongchun et al. (2017) Transitional basal cells at the squamous-columnar junction generate Barrett's oesophagus. Nature 550:529-533

Showing the most recent 10 out of 49 publications